infecti
requir
cleavag
furin
rekr
fl
motif
complex
wherea
kakr
sequenc
remain
uncleav
synthes
peptid
compris
studi
conform
vitro
furin
process
found
previous
report
analogu
repres
excel
vitro
furin
substrat
present
extend
sequenc
requir
heparin
optim
process
data
support
hypothesi
direct
bind
heparin
allow
select
exposureaccess
rekr
sequenc
optim
cleav
furin
human
immunodefici
viru
etiolog
agent
acquir
immunodefici
syndrom
aid
envelop
glycoprotein
process
host
proteas
heterodim
allow
viru
infect
target
cell
follow
cell
surfac
bind
trimer
complex
human
receptor
subsequ
coreceptor
interact
induc
conform
chang
lead
dissoci
allow
ntermin
fusion
peptid
insert
host
cell
membran
though
structur
monomer
core
complex
receptorfab
postfus
form
solv
littl
known
entir
env
conform
fact
individu
mimic
precursor
conform
two
monoclon
antibodi
direct
loop
recogn
env
precursor
cleav
proprotein
convertas
pc
furin
furin
likeproteas
rekr
fl
result
fusogen
complex
sinc
mutat
result
uncleav
noninfecti
viru
cleavag
essenti
viral
entri
vitro
investig
peptid
encompass
junction
confirm
cleavag
occur
arg
fl
interestingli
upstream
physiolog
process
site
second
potenti
furin
motif
kakr
ineffici
cleav
exact
role
unknown
though
mutat
kakr
sequenc
result
unprocess
precursor
conform
differ
may
explain
prefer
furin
even
though
short
peptid
effici
cleav
vitro
furin
arg
full
length
shown
effici
cleav
ex
vivo
suggest
structur
posttransl
modif
well
cellular
andor
extracellular
factor
may
also
influenc
efficaci
select
furin
mediat
cleavag
virus
sindbi
coronaviru
bind
target
cell
via
cellsurfac
glycosaminoglycan
gag
proteoglycan
also
shown
facilit
bind
entri
cell
lack
receptor
moreov
enzymat
remov
cell
surfac
heparan
sulfat
chain
drastic
impair
infect
cell
effect
like
implic
andor
interact
gag
mani
author
identifi
bind
site
heparin
deriv
within
loop
howev
increas
bodi
evid
point
possibl
interact
investig
influenc
sequenc
surround
rekr
motif
process
effici
synthes
variou
peptid
deriv
junction
tabl
moreov
measur
modul
role
gag
furin
process
evalu
effect
heparin
circular
dichroism
cd
hplc
found
junction
bind
heparin
thu
enhanc
furin
process
synthesi
report
synthes
semiautomat
synthes
appli
biosystem
mod
use
rink
amid
mbha
resin
abbrevi
human
immunodefici
viru
type
gag
glycosaminoglycan
cd
circular
dichroism
aid
acquir
immunodefici
syndrom
rphplc
revers
phase
high
perform
liquid
chromatographi
pc
proprotein
convertas
btmd
tran
membran
domain
ms
mass
spectrometri
amc
mca
tfe
trifluoroethanol
sd
sodium
dodecyl
sulfat
trishcl
tri
hydroxymethyl
aminomethanehcl
dmso
dimethyl
sulfoxid
hf
hydrofluor
acid
cmk
chloromethylketon
pb
phosphat
buffer
salin
novabiochem
la
jolla
mmolg
mmol
boc
chemistri
hbtuhobt
activ
detach
solid
support
remov
side
chain
protect
group
achiev
treat
hf
anisol
h
crude
product
purifi
revers
phase
high
perform
liquid
chromatographi
rphplc
delta
pak
hr
c
column
water
lm
mm
homogen
grade
evalu
rphplc
vydac
c
column
water
lm
mm
molecular
mass
check
electrospraytim
flight
tof
mass
spectrometri
ms
marin
apitof
cd
spectra
record
jasco
cd
spectropolarimet
model
cylindr
fuse
quartz
cell
path
length
cm
spectra
report
unit
mean
ellipt
peptid
molecular
weightnumb
amid
bond
h
r
deg
cm
dmol
ellipt
h
deg
cm
measur
perform
water
mm
phosphat
buffer
ph
mm
sodium
dodecyl
sulfat
sd
mm
phosphat
buffer
ph
trifluoroethanol
tfe
lm
heparin
sigma
low
molecular
weight
nacl
mm
tri
hydroxymethyl
aminomethanehcl
trishcl
buffer
ph
nacl
mm
trishcl
buffer
ph
peptid
concentr
determin
amino
acid
analysi
uv
absorpt
vari
lm
spectra
correct
solvent
salt
heparin
minor
contribut
media
cell
infect
either
wild
type
vaccinia
viru
vv
wt
control
solubl
form
hfurin
vv
hfurinbtmd
collect
h
postinfect
concentr
centriprep
activ
measur
fluorogen
substrat
pyrrtkrmca
assay
perform
lm
peptid
mm
cacl
mm
trishcl
buffer
ph
mm
bmercaptoethanol
furin
rel
fluoresc
unit
rfu
rfu
defin
pmol
amc
releasedminl
enzym
act
lm
fluorogen
substrat
pyrrtkrmca
control
media
vv
wt
cultur
supernat
specifi
incub
media
also
contain
lm
lm
lm
heparin
heparin
alon
show
enzymat
activ
shown
variou
time
point
sampl
analyz
rphplc
varian
c
column
lm
mm
digest
product
identifi
mass
spectrometri
ms
percent
cleavag
calcul
precursor
area
reaction
perform
mm
trishcl
mm
bmercaptoethanol
mm
cacl
ph
contain
lm
pyrrtkrmca
lm
substrat
furin
differ
concentr
lm
inhibitor
lm
decrvkrcmk
enzymat
activ
mcaconjug
peptidyl
substrat
monitor
nm
excit
nm
emiss
spectra
max
gemini
em
micropl
spectrofluoromet
molecular
devic
presenc
absenc
either
lm
lm
heparin
inhibit
assay
monitor
rphplc
ic
calcul
use
grafit
version
softwar
four
peptid
span
cleavag
sequenc
synthes
tabl
contain
includ
chosen
ref
extend
synthes
investig
influenc
region
surround
physiolog
cleavag
site
furin
process
report
cellperm
sequenc
kieplgvaptkakrrvvqrekr
contain
p
residu
interfer
process
thu
test
possibl
vitro
inhibitori
function
also
synthes
peptid
lgvaptkakrrvvqrekr
mimick
furinprocess
product
tabl
spectra
phosphat
buffer
ph
water
show
diagnost
band
minimum
nm
suggest
unstructur
fig
presenc
sd
red
shift
neg
band
observ
minimum
nm
fig
interestingli
base
nm
band
intens
micellar
solut
induc
assum
ahelix
conform
respect
fig
c
indic
like
sd
interact
could
due
insert
hydrophob
cterminu
micel
andor
could
result
electrostat
bind
posit
charg
andor
neg
charg
micellar
surfac
tfe
induc
order
structur
posit
band
nm
two
neg
nm
ahelix
content
tfeh
fig
sinc
cd
profil
neg
charg
sd
micellar
solut
show
transit
conform
toward
structur
popul
cleavag
site
posit
charg
conform
investig
perform
cd
profil
lm
heparin
similar
water
fig
chang
presenc
heparin
fig
contrast
cd
spectra
significantli
modifi
presenc
versu
absenc
heparin
fig
c
similar
result
obtain
higher
heparin
concentr
lm
peptid
digest
equal
well
furin
tabl
show
complet
process
h
fig
b
contrast
peptid
either
bare
unprocess
respect
even
h
digest
ph
fig
b
tabl
sinc
vitro
cleavag
report
optim
ph
assay
perform
acid
condit
ph
reveal
differ
respect
result
obtain
ph
furthermor
similar
data
observ
presenc
low
level
denatur
sd
shown
first
hypothes
product
inhibit
could
explain
result
thu
test
vitro
abil
peptid
repres
furinderiv
product
tabl
inhibit
process
either
fluorogen
pyrrtkrmca
peptid
peptid
effect
reduc
releas
free
amc
estim
ic
lm
fig
could
partial
inhibit
process
ic
lm
fig
conclud
product
inhibit
explain
inabl
furin
process
peptid
cd
investig
show
like
bind
heparin
fig
c
four
analogu
digest
overnight
absenc
presenc
lm
heparin
condit
digest
similar
rate
independ
presenc
heparin
contrast
signific
process
occur
absenc
heparin
process
rekrfl
site
product
ident
retent
time
rphplc
synthet
version
peptid
respect
observ
presenc
lm
heparin
fig
control
confirm
peptid
cleav
recombin
vv
wtinfect
cultur
supernat
fig
upper
center
panel
furthermor
cleavag
inhibit
ad
well
known
pcinhibitor
decrvkrcmk
fig
upper
right
panel
lm
heparin
obtain
extens
process
also
notic
precipit
peptid
shown
final
separ
h
furin
incub
experi
process
peptid
also
show
similar
enhanc
effect
heparin
shown
conclus
data
indic
like
heparinpeptid
interact
may
better
expos
henc
allow
effect
furin
cleavag
five
peptid
tabl
span
junction
investig
better
defin
glycoprotein
cleavag
shorter
analogu
process
furin
rekr
kakr
includ
uncleav
fig
lack
process
may
ration
basi
structur
motif
fact
nmr
molecular
model
tfe
reveal
embed
helic
segment
wherea
expos
loop
cterminu
peptid
contrast
span
extens
sequenc
cleavag
region
shown
repres
poor
furin
substrat
suggest
gener
fragment
could
either
act
inhibitor
extend
region
surround
physiolog
cleavag
site
prevent
effect
process
sinc
possibl
product
inhibit
exclud
turn
attent
toward
structur
restrict
andor
need
factor
ration
noncleav
peptid
cd
analysi
aqueou
solut
reveal
three
analogu
unstructur
yet
digest
furin
thu
structur
constraint
must
exist
least
around
argument
may
explain
inabl
furin
cleav
substrat
use
attempt
increas
process
ad
deterg
enhanc
peptid
backbon
flexibl
without
affect
enzym
activ
howev
neither
sd
effect
therefor
suspect
cellularextracellular
factor
may
influenc
cleavabl
furin
inde
surfac
protein
contain
heparinbind
motif
process
furin
report
particular
sindbi
viru
attach
target
cell
enhanc
presenc
heparan
sulfat
hs
via
furin
recognit
motif
unprocess
envelop
glycoprotein
similarli
peptid
deriv
cleavag
site
human
respiratori
syncyti
viru
rsv
fusion
glycoprotein
bind
heparin
cellular
gag
sinc
form
stabl
trimer
unprocess
hypothes
oligom
attach
plasma
membran
heparin
sulfat
occur
via
furin
cleavag
site
inde
kakr
rvvqrekr
sequenc
exhibit
basic
region
contain
two
potenti
invert
consensu
hsbind
domain
thu
shown
affin
heparin
higher
observ
impli
andor
hidden
motif
matur
may
involv
heparin
bind
cd
spectra
suggest
peptid
could
interact
heparin
fig
undergo
structur
reorgan
fact
presenc
heparin
profil
chang
respect
peptid
alon
neg
band
nm
diagnost
aperiod
structur
replac
posit
one
contrast
noteworthi
shorter
chang
cd
profil
presenc
heparin
sinc
differ
lie
hydrophob
residu
interact
heparin
polypeptid
suppos
electrostat
addit
residu
may
support
favor
peptid
conform
optim
orient
posit
charg
side
chain
toward
neg
charg
sulfat
moieti
result
agre
probabl
interact
propos
suggest
residu
span
junction
may
contribut
bind
moreov
given
heparin
induc
chang
conform
could
play
key
role
enzymesubstr
recognit
analyz
may
influenc
furin
process
surprisingli
lm
heparin
influenc
furin
activ
pyrrtkrmca
process
fig
left
upper
panel
peptid
digest
fig
therefor
hypothes
heparin
induc
conform
chang
optim
expos
furincleavag
rekr
site
first
time
heparin
shown
enhanc
vitro
cleavag
precursor
furin
conclus
studi
shown
absenc
heparin
deriv
peptid
repres
poor
furin
substrat
vitro
contrast
shorter
analogu
effici
process
heparin
shown
strongli
interact
peptid
induc
conform
chang
therebi
expos
cleavag
sinc
peptid
may
faith
mimic
conform
around
cleavag
site
within
complet
precursor
analys
requir
assess
heparin
essenti
vivo
matur
gag
modul
activ
